Search Results

BELLUS Health Inc. has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 billion pursuant to a plan of arrangement.

BELLUS Health Inc. announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting of shareholders of BELLUS on June 16, 2023.

BELLUS Health Inc. reported its financial and operating results for the quarter ended March 31, 2023.

BELLUS Health Inc. today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held March 6 - 8, 2023 in Boston, MA.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022.

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion).

BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.

BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), today reported its financial and operating results for the second quarter ending June 30, 2022.